NCT00400660 is a Phase 1 clinical trial of GSK615915A in Bronchospasm, sponsored by GlaxoSmithKline.

Who is sponsoring NCT00400660?

NCT00400660 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT00400660?

Interventions in NCT00400660: GSK615915A, Placebo.

What condition does NCT00400660 study?

NCT00400660 studies Bronchospasm.

Is NCT00400660 still recruiting?

NCT00400660 is currently completed. Last updated 29 September 2017.

Last reviewed 2017-09-29 · How we verify

NCT00400660

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A First Time In Human Study To Assess The Compound GSK615915

Completed Phase 1 Last updated 29 September 2017

What this trial tests

Phase 1 trial testing GSK615915A in Bronchospasm in 46 participants. Completed in 3 July 2006.

Timeline

23 November 2005

Primary endpoint
3 July 2006

3 July 2006

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Primary purpose	treatment
Enrollment	46
Start date	23 November 2005
Primary completion	3 July 2006
Estimated completion	3 July 2006
Sites	1 location across United Kingdom

Drugs / interventions tested

GSK615915A — full drug profile →
Placebo

Conditions studied

Bronchospasm — all drugs for Bronchospasm →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

Adults 18 to 60, any sex, with Bronchospasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

GSK615915A is being developed as a novel surfactant for use in the formulation of GSK's future generation of Metered Dose Inhalers (MDIs). A surfactant in a MDI would provide a more stable drug suspension, this in turn will produce a consistent dose of drug being delivered with each puff.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Bronchospasm

Currently open trials in the same condition.

NCT07211529 — Intraoperative Paravertebral Block and Postoperative Complications · NA · recruiting

Other GlaxoSmithKline trials

Trials by the same sponsor.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00400660 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 29 September 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00400660.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing